Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation?

Area of Science:

• Immunology and Inflammation
• Gastroenterology
• Critical Care Medicine

Background:

• Systemic inflammatory response syndromes (SIRS), particularly sepsis, pose significant challenges in modern medicine.
• Current therapeutic strategies targeting tumor necrosis factor alpha (TNFα) and glucocorticoids (GCs) for sepsis have yielded controversial or frustrating results.
• The intestinal epithelium is a critical TNF-responsive target during SIRS.

Purpose of the Study:

• To explore the role of the intestinal epithelium in SIRS and sepsis.
• To evaluate the potential of targeting TNF receptor 1 (TNFR1) as a therapeutic approach.
• To investigate the interplay between GCs and TNF within intestinal epithelial cells (IECs).

Main Methods:

• Review of existing literature on SIRS, sepsis, TNFα, GCs, TNFR1, and intestinal epithelial cells (IECs).
• Analysis of the therapeutic implications of targeting TNFR1 specifically in IECs.
• Exploration of combining IEC-specific TNFR1 targeting with IEC-specific glucocorticoid receptor (GR) stimulation.

Main Results:

• Inhibition of TNFR1, rather than TNF itself, may represent a more targeted and safer therapeutic strategy in SIRS.
• A significant interplay exists between GCs and TNF within IECs, suggesting a localized therapeutic window.
• Targeting GCs within IECs could circumvent dose-limiting off-target effects seen with systemic administration.

Conclusions:

• Targeting TNFR1 specifically within IECs offers a promising approach for treating SIRS and sepsis.
• Combining IEC-specific TNFR1 targeting with IEC-specific GR stimulation could enhance treatment safety and efficacy.
• This localized therapeutic strategy may overcome the limitations and controversies associated with current systemic treatments for sepsis.